Eisai Cuts U.S. Jobs In ‘Realignment’
This article was originally published in PharmAsia News
Eisai is cutting a little over 200 people from its U.S. commercial and regional corporate services units in what the Japanese pharma firm is dubbing a "realignment of its US operations." The move follows weaker than expected sales for several new drugs.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.